Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models

Baragi, Vijaykumar M., Becher, Gabriel, Bendele, Alison M., Biesinger, Ralf, Bluhm, Harald, Boer, Jürgen, Deng, Hongbo, Dodd, Rory, Essers, Michael, Feuerstein, Tim, Gallagher, Brian M., Gege, Christian, Hochgürtel, Matthias, Hofmann, Michael, Jaworski, Andreas, Jin, Lixia, Kiely, Andrew, Korniski, Brian, Kroth, Heiko, Nix, Darrell, Nolte, Bert, Piecha, Dorothea, Powers, Timothy S., Richter, Frank, Schneider, Matthias, Steeneck, Christoph, Sucholeiki, Irving, Taveras, Arthur, Timmermann, Andreas, Van Veldhuizen, Joshua, Weik, Juergen, Wu, Xinyuan, Xia, Bing·2009·Arthritis & Rheumatism

Abstract

Objective: Matrix metalloproteinases (MMPs) have long been considered excellent targets for osteoarthritis (OA) treatment. However, clinical utility of broad‐spectrum MMP inhibitors developed for this purpose has been restricted by dose‐limiting musculoskeletal side effects observed in humans. This study was undertaken to identify a new class of potent and selective MMP‐13 inhibitors that would provide histologic and clinical efficacy without musculoskeletal toxicity. Methods: Selectivity assays were developed using catalytic domains of human MMPs. Freshly isolated bovine articular cartilage or human OA cartilage was used in in vitro cartilage degradation assays. The rat model of monoiodoacetate (MIA)–induced OA was implemented for assessing the effects of MMP‐13 inhibitors on cartilage degradation and joint pain. The surgical medial meniscus tear model in rats was used to evaluate the chondroprotective ability of MMP‐13 inhibitors in a chronic disease model of OA. The rat model of musculoskeletal side effects (MSS) was used to assess whether selective MMP‐13 inhibitors have the joint toxicity associated with broad‐spectrum MMP inhibitors. Results: A number of non–hydroxamic acid–containing compounds that showed a high degree of potency for MMP‐13 and selectivity against other MMPs were designed and synthesized. Steady‐state kinetics experiments and Lineweaver‐Burk plot analysis of rate versus substrate concentration with one such compound, ALS 1‐0635, indicated linear, noncompetitive inhibition, and Dixon plot analysis from competition studies with a zinc chelator (acetoxyhydroxamic acid) and ALS 1‐0635 demonstrated nonexclusive binding. ALS 1‐0635 inhibited bovine articular cartilage degradation in a dose‐dependent manner (48.7% and 87.1% at 500 n M and 5,000 n M, respectively) and was effective in inhibiting interleukin‐1α– and oncostatin M–induced C1,C2 release in human OA cartilage cultures. ALS 1‐0635 modulated cartilage damage in the rat MIA model (mean ± SEM damage score 1.3 ± 0.3, versus 2.2 ± 0.4 in vehicle‐treated animals). Most significantly, when treated twice daily with oral ALS 1‐0635, rats with surgically induced medial meniscus tear exhibited histologic evidence of chondroprotection and reduced cartilage degeneration, without observable musculoskeletal toxicity. Conclusion: The compounds investigated in this study represent a novel class of MMP‐13 inhibitors. They are mechanistically distinct from previously reported broad‐spectrum MMP inhibitors and do not exhibit the problems previously associated with these inhibitors, including selectivity, poor pharmacokinetics, and MSS liability. MMP‐13 inhibitors exert chondroprotective effects and can potentially modulate joint pain, and are, therefore, uniquely suited as potential disease‐modifying osteoarthritis drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.24629

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 174

Metadata

Authors
Baragi, V. M., Becher, G., Bendele, A. M., Biesinger, R., Bluhm, H., Boer, J., Deng, H., Dodd, R., Essers, M., Feuerstein, T., Gallagher, B. M., Gege, C., Hochgürtel, M., Hofmann, M., Jaworski, A., Jin, L., Kiely, A., Korniski, B., Kroth, H., Nix, D., Nolte, B., Piecha, D., Powers, T. S., Richter, F., Schneider, M., Steeneck, C., Sucholeiki, I., Taveras, A., Timmermann, A., Van Veldhuizen, J., Weik, J., Wu, X., & Xia, B.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2009-06-29
Volume
60
Issue
7
Pages
2008-2018
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2065173081
Cited by
174
References
1
FWCI
4.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.